Leukemia cancer cells before and after new drug treatment.
CREDIT
Waleed Minzel/Hebrew University.
Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
Learn more: For first time in 40 years, cure for acute leukemia within reach
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- New drug combination may help treat acute myeloid leukemiaon January 19, 2021 at 8:48 am
Researchers able to significantly enhance cancer cell death by jointly administering MDM2 inhibitors and BET inhibitors Researchers have identified two drugs that are potent against acute myeloid ...
- Unleashing the cancer-fighting gene TP53 in leukemia with a novel combination treatmenton January 19, 2021 at 5:41 am
Drugs that target the cancer-promoting proteins MDM2 and BET have been tried in acute myeloid leukemia (AML) but haven’t been all that effective on their own. In a new study, combining the two ...
- New drug combination shows promise as powerful treatment for AMLon January 19, 2021 at 12:37 am
Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone. The researchers were able to significantly enhance ...
- Researchers identify new drug combination that can treat acute myeloid leukemiaon January 18, 2021 at 11:26 pm
Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone.
- Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Projecton January 14, 2021 at 11:11 am
Genetic testing expert Invitae has received the backing of some of the largest pharmaceutical companies in the industry. Bristol Myers Squibb , Johnson & Johnson , Novartis , and ...
- Augmented RIC No Help in Transplant for AMLon January 12, 2021 at 10:33 am
A sequential augmented reduced-intensity conditioning (RIC) regimen failed to improve post-transplant outcomes for patients with high-risk acute myeloid leukemia (AML) or myelodysplasia (MDS), a ...
- Health Canada Approves ONUREG® (azacitidine tablets), First Maintenance Therapy for Patients in Remission from Acute Myeloid Leukemiaon January 12, 2021 at 4:41 am
ONUREG® has shown clinically meaningful increase in overall survival for patients MONTREAL, Jan. 12, 2021 /CNW/ - Bristol Myers Squibb Canada ...
- Acute Myeloid Leukemia Treatment Market 2020 Key Dynamics, Recent and Future Demand, Trend, Analysis upto 2027on January 10, 2021 at 6:56 pm
Global " Acute Myeloid Leukemia Treatment Market" 2020 report includes the market strategy, market orientation, ...
- IU research findings could prevent common complication of blood stem cell transplantation in leukemiaon January 7, 2021 at 5:10 pm
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to ...
- Leukemia: New Adverse Event With PARP Inhibitors in Canceron January 7, 2021 at 10:52 am
Late toxicities in the form of myelodysplastic syndrome and acute myeloid leukemia can occur even a brief exposure to PARP inhibitors, and both are associated with a high mortality rate.
via Bing News
